Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.91 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19248153 | 0.95 | HSD11B1 (1.00) | HSD11B1MEN1KMT2ALMNAGAA | |
| SCHEMBL12089633 | 0.86 | HSD11B1 (0.82) | HSD11B1MEN1KMT2AGAAMAPT | |
| SCHEMBL3604356 | 0.81 | HSD11B1 (0.71) | HSD11B1MEN1KMT2ALMNAMAPT | |
| SCHEMBL3609740 | 0.81 | HSD11B1 (0.62) | HSD11B1MEN1KMT2ALMNAGAA | |
| SCHEMBL4402433 | 0.79 | LMNA (0.90) | HSD11B1MEN1KMT2ALMNAGAA | |
| SCHEMBL21681941 | 0.79 | ALDH1A1 (0.74) | HSD11B1MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL17918 | 0.79 | GCK (0.73) | HSD11B1MEN1KMT2AGAAMAPT | |
| SCHEMBL11508440 | 0.79 | POLB (0.75) | HSD11B1MEN1KMT2ALMNAGAA | |
| SCHEMBL1711126 | 0.79 | HSD11B1 (0.70) | HSD11B1MEN1KMT2ALMNAGAA | |
| SCHEMBL11507901 | 0.78 | HSD11B1 (0.70) | HSD11B1MEN1KMT2ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637527-B1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL (JP) | 2013-04-17 | — | — | EP | claimed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | claimed |
| US-20070099990-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | claimed |
| EP-1637527-A1 | CANNABINOID RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2006-03-22 | — | — | EP | claimed |
| EP-1637527-B1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-7825122-B2 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825122-B2 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825122-B2 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-23 | — | — | US | disclosed |
| US-7507841-B2 | Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20090023800-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-01-22 | — | — | US | disclosed |
| US-7465815-B2 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20080021087-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-01-24 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| WO-2007070506-A2 | DIAZA HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070506-A2 | DIAZA HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070099990-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| EP-1637527-A1 | CANNABINOID RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | GLP1R, GPR119, INSR | HSD11B1 685/4885MEN1 1597/4885KMT2A 821/4885 |
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | CNR1, CNR2, GPR18 | HSD11B1 941/4885MEN1 3532/4885KMT2A 1061/4885 |
| US-20080021087-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | HSD11B1 941/4885MEN1 3532/4885KMT2A 1061/4885 |
| US-20090023800-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | HSD11B1 941/4885MEN1 3532/4885KMT2A 1061/4885 |
| US-20070099990-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | HSD11B1 941/4885MEN1 3532/4885KMT2A 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.